CRDF Company Profile and Key Details

Q: Who are the executives of CRDF?

Dr. Tod Smeal Ph.D.Chief Scientific Officer?Dr. Mark Erlander Ph.D.Chief Executive Officer & DirectorMr. James E. LevineChief Financial OfficerMs. Vicki KelemenChief Operating OfficerDr. Fairooz Kabbinavar FACP, M.D.Chief Medical OfficerMr. Charles Monahan R.Ph.Senior Vice President of Regulatory AffairsMs. Elizabeth AndersonVice President of Fin. & Admin.Ms. Brigitte LindsaySenior Vice President of Fin.

NASDAQ : CRDF

Cardiff Oncology

$1.21

0.16+15.24%

At Close 4:00 PM

$1.25

+0.04+3.06%

After-Market 06:00 PM

66.45

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cardiff Oncology, Inc. (CRDF) stock surged +15.24%, trading at $1.21 on NASDAQ, up from the previous close of $1.05. The stock opened at $1.05, fluctuating between $1.03 and $1.22 in the recent session.

Stock Snapshot

1.05

Prev. Close

93.26M

Market Cap

1.0301

Day Low

-2.02

P/E Ratio

-0.6

EPS (TTM)

-0.7

Cash Flow per Share

1.05

Open

77.07M

Number of Shares

1.22

Day High

97.55%

Free Float in %

1.56

Book Value

725.7K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	1.05	1.22	1.03	1.21	726.13K
Sep 09, 2026	1.08	1.08	1.02	1.05	715.98K
Sep 08, 2026	1.05	1.13	1.05	1.10	703.17K
Sep 04, 2026	1.08	1.10	1.07	1.09	437.32K
Sep 03, 2026	1.07	1.09	1.04	1.08	375.49K
Sep 02, 2026	1.04	1.09	1.01	1.06	700.78K
Sep 01, 2026	1.01	1.07	1.00	1.03	838.85K
Aug 31, 2026	0.94	1.01	0.90	0.99	590.39K
Aug 28, 2026	0.99	0.99	0.93	0.94	526.82K
Aug 27, 2026	0.98	1.00	0.98	0.99	202.19K
Aug 26, 2026	1.02	1.02	0.98	0.98	274.27K
Aug 25, 2026	1.00	1.07	0.98	1.02	918.43K
Aug 24, 2026	0.94	1.05	0.93	1.00	1.68M
Aug 21, 2026	0.93	0.93	0.88	0.88	651.82K
Aug 20, 2026	0.91	0.92	0.87	0.91	554.19K
Aug 19, 2026	0.89	0.91	0.88	0.90	564.78K
Aug 18, 2026	0.90	0.93	0.87	0.89	597.13K
Aug 17, 2026	0.95	0.96	0.90	0.90	586.76K
Aug 14, 2026	0.98	1.02	0.96	0.96	481.03K
Aug 13, 2026	0.99	1.06	0.96	0.98	599.27K

Contact Details

San Diego, CA 92121

United States

https://www.cardiffoncology.com 858 952 7570

About Company

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Stock Peers

ARGX

-18.27-1.82%

argenx SE$984.04 REGN

-14.39-1.78%

Regeneron Pharmaceuticals, Inc.$793.26 MDGL

-13.54-2.48%

Madrigal Pharmaceuticals, Inc.$533.12 VRTX

-6.56-1.26%

Vertex Pharmaceuticals Incorporated$514.56 UTHR

-2.96-0.58%

United Therapeutics Corporation$503.86 KRYS

-2.54-0.73%

Krystal Biotech, Inc.$345.55 ONC

-9.2-2.62%

BeOne Medicines AG$341.80 PRAX

-6.73-1.95%

Praxis Precision Medicines, Inc.$338.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

1.2+0.42%

Ligand Pharmaceuticals Incorporated$289.25

Company Overview

Cardiff Oncology, Inc. (NASDAQ:CRDF) closed at $1.21 USD, gaining $0.16 (15.24%) from the previous close of $1.05. The stock is currently mid-range between its 52-week high and low $0.76 and $3.31. With a market capitalization of about $93.26 million, Cardiff Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.46). Key stats such as the average daily volume over the past year has been around 1.22 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Cardiff Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mani Mohindru, the company employs approximately 31 people and listed since July 27, 2004. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 19.46%, SMA50 -15.66%, SMA200 -24.66%). The stock’s 14-day RSI is 52.9 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.97% below its high and over 32.43% above its low. Average 10-day trading volume of 636.01 thousand shares is below the 3-month average of 1.21 million, indicating normal recent market interest.

Valuation Metrics

Cardiff Oncology, Inc. trades at a P/E ratio of -1.89, slightly below the S&P 500 average, with a price-to-sales ratio of 172.13 and a price-to-book ratio of 2.92 suggesting the stock is closer to book value. The P/FCF stands at -2.14, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Cardiff Oncology, Inc. generated EPS of -$0.69 over the past year. Five-year average earnings growth is 8.71%. Wall Street analysts project EPS growth of -17.0% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.15. Next year's EPS is expected at -$21.27. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $2.00. The high target offers 726.45% upside. The low target suggests 65.29% downside. The mean target is $7.33. This offers 505.79% upside. Cardiff Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 17.03%. The prior quarter beat by 38.46%. Over the last six quarters, Apple has recorded several small beats. These include 5.26% in May 08, 2025.

Shareholding & Insider Activity

Cardiff Oncology, Inc. has 77.80 million shares outstanding. The public float is 75.36 million shares, elevated short interest at 16.00% of float. This equals 12.19 million shares. The short ratio is 7.54 days. Institutional investors hold 30.72% of the float. Insiders own 6.12%. Hunter Robert Merrill holds 4.00 million shares, BRIDGER MANAGEMENT, LLC has 2.97 million shares and CERRONE GABRIEL has 719.53 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cardiff Oncology generated $488.00K in revenue, or $0.01 per share. Gross margin was 18.44%, operating margin -9305.74%, and net profit margin -8492.01%. Returns are negative, with ROA at -50.76% and ROE at -59.42%.
On valuation metrics, Cardiff Oncology trades at a P/E of -1.89, P/S of 172.13 and P/B of 2.92. The current ratio is 3.30 and quick ratio is 3.30. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 135.80 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -89.40.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cardiff Oncology posted revenue of $488.00K, down slightly from $386.00K in the prior quarter. Gross profit was $90.00K (margin 18.44%). Operating income was - $45.41M (margin -9305.7%). Net income was- $41.44M (EPS - $0.93).
The company ended the quarter with $74.82M in cash and short-term investments, a total debt of $2.15M, and net debt of - $19.51M. Total assets were $81.64M, with equity of $69.74M. Financials further reflected weakness, with operating cash flow of - $30.89M, free cash flow of - $31.47M, and capital expenditures of - $582.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Cardiff Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.61%, with price expected at $1.13 by September 23, 2026, within a range of $1.06 to $1.20 3-Month Outlook: Projected rise of 58.68%, reaching $1.92 by December 08, 2026, with a range of $1.49 to $2.12.

Key Takeaways

Cardiff Oncology, Inc. (NASDAQ:CRDF) shares are flat 0.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cardiff Oncology, Inc. trading at a premium to the broader market with a P/E of -1.89. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $13.36, suggesting 1004.13% upside.

Frequently Asked Questions

What is the current Cardiff Oncology, Inc. (CRDF) stock price?

Cardiff Oncology, Inc. (NASDAQ: CRDF) stock price is $1.21 in the last trading session. During the trading session, CRDF stock reached the peak price of $1.22 while $1.03 was the lowest point it dropped to. The percentage change in CRDF stock occurred in the recent session was 15.24% while the dollar amount for the price change in CRDF stock was $0.16.

CRDF's industry and sector of operation?

The NASDAQ listed CRDF is part of Biotechnology industry that operates in the broader Healthcare sector. Cardiff Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CRDF?

Dr. Tod Smeal Ph.D.
Chief Scientific Officer?
Dr. Mark Erlander Ph.D.
Chief Executive Officer & Director
Mr. James E. Levine
Chief Financial Officer
Ms. Vicki Kelemen
Chief Operating Officer
Dr. Fairooz Kabbinavar FACP, M.D.
Chief Medical Officer
Mr. Charles Monahan R.Ph.
Senior Vice President of Regulatory Affairs
Ms. Elizabeth Anderson
Vice President of Fin. & Admin.
Ms. Brigitte Lindsay
Senior Vice President of Fin.

How CRDF did perform over past 52-week?

CRDF's closing price is 59.21% higher than its 52-week low of $0.76 where as its distance from 52-week high of $3.31 is -63.44%.

How many employees does CRDF have?

Number of CRDF employees currently stands at 31.

Link for CRDF official website?

Official Website of CRDF is: https://www.cardiffoncology.com

How do I contact CRDF?

CRDF could be contacted at phone 858 952 7570 and can also be accessed through its website. CRDF operates from 11055 Flintkote Avenue, San Diego, CA 92121, United States.

How many shares of CRDF are traded daily?

CRDF stock volume for the day was 725.7K shares. The average number of CRDF shares traded daily for last 3 months was 1.22M.

What is the market cap of CRDF currently?

The market value of CRDF currently stands at $93.26M with its latest stock price at $1.21 and 77.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	31
Beta	1.44
Sales or Revenue	$488.00K
5Y Sales Change%	-0.933%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CRDF Company Profile and Key Details

Cardiff Oncology

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook